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Background: Omega-3 fatty acids are known to prevent cardiac death. However, previous observational studies
have suggested that omega-3 fatty acids are associated with cancer risk in adults. We conducted a meta-analysis
based on randomized controlled trials to evaluate the effect of omega-3 fatty acids on the risk of cancer incidence,
nonvascular death, and total mortality.
Methods: In February 2013, we performed electronic searches in PubMed, EmBase, and the Cochrane Library to
identify randomized controlled trials on cancer incidence, nonvascular death, and total mortality. Relative risk (RR)
was used to measure the effect of omega-3 fatty acid supplementation on the risk of cancer incidence, nonvascular
death, and total mortality using a random-effect model. The analysis was further stratified by factors that could
affect the treatment effects.
Results: Of the 8,746 identified articles, we included 19 trials reporting data on 68,954 individuals. These studies
reported 1,039 events of cancer, 2,439 events of nonvascular death, and 7,025 events of total mortality. Omega-3
fatty acid supplementation had no effect on cancer incidence (RR, 1.10; 95% CI: 0.97–1.24; P = 0.12), nonvascular
death (RR, 1.00; 95% CI: 0.93–1.08; P = 1.00), or total mortality (RR, 0.95; 95% CI: 0.88–1.03; P = 0.24) when compared
to a placebo. Subgroup analysis indicated that omega-3 fatty acid supplementation was associated with a reduction
in total mortality risk if the proportion of men in the study population was more than 80%, or participants received
alpha-linolenic acid.
Conclusions: Omega-3 fatty acid supplementation does not have an effect on cancer incidence, nonvascular death,
or total mortality.
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Omega-3 fatty acid supplementation has been suggested to
reduce the risk of cancer incidence [1-3], including that of
colorectal [1], lung [2], and prostate [3] cancers. However,
observational studies often overestimate the size of the ef-
fect and do not prove causality. Omega-3 fatty acid-derived
eicosanoids influence many physiological processes such as* Correspondence: zhou_ly@126.com
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reproduction in any medium, provided the orcalcium transport across cell membranes, angiogenesis,
apoptosis, cell proliferation, and immune cell function
[4-6], all of which might play a role in cancer risk.
Omega-3 fatty acid supplementation has been studied
in numerous, large-scale, randomized, controlled trials
for primary and secondary prevention of cardiovascular
outcomes [7-17]. We could gain insight into the risk of
cancer between omega-3 fatty acid supplementation and
a placebo, with a study involving a long-term follow-up
period and proper collection of cancer data. Therefore,
we conducted a systematic review and meta-analysis
of pooled data from randomized controlled trials toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mentation on cancer incidence, nonvascular death, and
total mortality.
Methods
Data sources, search strategy, and selection criteria
This review was conducted and reported according to
the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) Statement [18], issued in
2009 (Additional file 1: Table S1). Randomized con-
trolled trials of omega-3 fatty acid supplementation,
written in the English language, were eligible for inclu-
sion in our meta-analysis, regardless of the publication
status (published, in press, or in progress), and the ef-
fects of omega-3 fatty acid supplementation on cancer
incidence, nonvascular death, and total mortality were
examined. Relevant trials were identified using the fol-
lowing procedure:
(1) Electronic searches: we searched the PubMed,
EmBase, and Cochrane Central Register of Controlled
Trials electronic databases for articles published through
February 2013 and used “linolenic acid” OR “timnodonic
acid” OR “ALA” OR “EPA” OR “docosahexaenoic acid”
OR “DHA” OR “omega-3 fatty acid” OR “fish oil” AND
“randomized controlled trials” AND “clinical trials”
AND “human” as the search terms. All reference lists
from reports on non-randomized controlled trials were
searched manually for additional eligible studies.
(2) Other sources: we searched ongoing randomized con-
trolled trials in the metaRegister of Controlled Trials, which
lists trials that are registered as completed but not yet pub-
lished. Furthermore, we reviewed bibliographies of publica-
tions for potentially relevant trials. Medical subject headings,
methods, patient population, interventions, and outcomes
variables of these studies were used to identify relevant trials.
The literature search, data extraction, and quality assessment
were undertaken by two authors (YFZ and AJH), independ-
ently with a standardized approach. Any inconsistencies
between these 2 authors (YFZ and AJH) were settled by
the primary author (YHZ) until a consensus was reached.
We restricted our research to randomized controlled tri-
als, which were less likely to be subjected to confounding
variables or bias views than observational studies. The
study was eligible for inclusion if the following criteria
were met: (1) the study was a randomized controlled trial;
(2) the trial evaluated the effects of omega-3 fatty acid
supplementation compared to a placebo; (3) the duration
of the study’s follow-up period was at least 6 months; and
(4) the trial reported at least 1 outcome as either cancer
incidence, nonvascular death, or total mortality.
Data collection and quality assessment
All data from eligible trials were independently ab-
stracted, in duplicate, by 2 independent investigators(YFZ and HFG) with a standard protocol and reviewed
by a third investigator (YHZ). Any discrepancies were
resolved by a group discussion. The data collected
included baseline characteristics (first author or study
group’s name, publication year, study design, type of
blinding, number of patients, mean age, percentage of
males, patient diseases, intervention regimes, and the
duration of the follow-up period). The outcomes investi-
gated included cancer incidence, nonvascular death, and
total mortality. Study quality was assessed using the
Jadad score [19], which is based on the 5 following sub-
scales: randomization (1 or 0), concealment of the treat-
ment allocation (1 or 0), blinding (1 or 0), completeness
of follow-up (1 or 0), and the use of intention-to-treat
analysis (1 or 0). A “score system” (ranging from 1 to 5)
has been developed for quality assessment. In our study,
we considered a study given a score of 4 or above to be
a high-quality study.
Statistical analysis
We allocated the results of each randomized controlled
trial as dichotomous frequency data. Individual study
relative risks (RRs) and 95% confidence intervals (CIs)
were calculated from event numbers extracted from each
trial before data pooling. The overall RR and 95% CIs of
cancer incidence, nonvascular death, and total mortality
were also calculated. Both fixed-effect and random-
effects models were used to assess the pooled RR for
omega-3 fatty acid supplementation compared to a pla-
cebo. Although both models yielded similar findings, re-
sults from the random-effects model presented here
assume that the true underlying effect varies among in-
cluded trials [20,21]. Heterogeneity of the treatment ef-
fects between studies was investigated visually by a
scatter plot analysis as well as statistically using the het-
erogeneity I2 statistic [22,23]. We explored potential het-
erogeneity in estimates of the treatment effects with
univariate meta-regression (for sample size, mean age,
percent men, and duration of the follow-up period) [24].
Subsequently, subgroup analyses were conducted on the
basis of publication year, number of patients, percent
men, mean age, intervention, primary or secondary pre-
vention, duration of the follow-up period, and the Jadad
score [19]. Interaction tests [25] were performed to com-
pare differences between estimates of the 2 subsets,
which were based on Student t distribution rather than
on normal distribution because the number of inclusive
studies was small. We also performed a sensitivity ana-
lysis by removing each individual trial from the meta-
analysis. Visual inspections of funnel plots for cancer in-
cidence, nonvascular death, and total mortality were
conducted. The Egger [26] and Begg tests [27] were also
used to statistically assess publication bias for cancer
incidence, nonvascular death, and total mortality. All
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were considered statistically significant for all included
studies. Statistical analyses were performed using STATA
software (version 10.0).Results
We identified 8,746 articles from our initial electronic
search, of which 8,314 were excluded during an initial
review (title and abstract). We retrieved the full text for
the remaining 432 articles, and 19 randomized con-
trolled trials [7-17,28-35] met the inclusion criteria
(Figure 1 and Additional file 2: Figure S1). Table 1 sum-
marizes the characteristics of these trials and the
important baseline information of the included 68,954
individuals. The trials included in this study compared
omega-3 fatty acid supplementation to a placebo for
cancer incidence, nonvascular death, and total mortality.
The follow-up period for participants ranged from 10 to
74.4 months, and the number of individuals included in
each trial ranged from 36 to 18645. The breakdown for
the number of trials available for each outcome were 11,
16, and 17 for cancer incidence [7-17], nonvascular death
[7,8,11-16,28-35], and total mortality [7,8,11-17,28-35], re-
spectively. We restricted the inclusion criteria to random-
ized controlled trials with a 6-month minimum follow-up
to ensure a reliable conclusion. Although the included tri-
als scarcely reported on the key indicators of trial quality,
the quality of the trials was also assessed by the Jadad
score [19]. Overall, 4 trials had a Jadad score of 5, 7 trials
had a score of 4, 4 trials had a score of 3, 2 trials had a
score of 2, and the remaining 2 trials had a score of 1.Figure 1 Flow diagram of the literature search and trials
selection process.Data for the effect of omega-3 fatty acid supplementa-
tion on cancer incidence included 39,122 individuals and
reported 1,039 cancer events. Overall, omega-3 fatty acid
supplementation increased the risk of cancer incidence
by 10%, but this increase was not statistically significant
(RR, 1.10; 95% CI: 0.97–1.24; P = 0.12, without evidence
of heterogeneity, Figure 2). A sensitivity analysis indi-
cated that the results were not affected by sequential ex-
clusion of any particular trial from all pooled analysis.
Similarly, the non-significant response persisted after a
cumulative meta-analysis for cancer incidence was con-
ducted (Additional file 3: Figure S2).
Data for the effect of omega-3 fatty acid supplementa-
tion on nonvascular death included 66,204 individuals
and 2,439 events of nonvascular death. There were
no differences observed between participants receiving
omega-3 fatty acid versus those receiving the placebo for
nonvascular death (RR, 1.00; 95% CI: 0.93–1.08; P = 1.00,
Figure 3), and no statistical heterogeneity was observed
between trials (P = 0.94). After sequential exclusion of
each trial from all pooled analysis, the results were not
affected by exclusion of any specific trial. In a cumula-
tive meta-analysis for nonvascular death (Additional file
4: Figure S3), the omega-3 fatty acid effect remained un-
changed, i.e., not statistically significant.
Data for the effect of omega-3 fatty acid supplementa-
tion on total mortality included 68,705 individuals and
reported 7,025 total mortality events. We noted that
omega-3 fatty acid supplementation showed a 5% reduc-
tion in total mortality; however, there was no supporting
evidence to show that omega-3 fatty acid protected
against total mortality risk (RR, 0.95; 95% CI: 0.88–1.03;
P = 0.24, Figure 4). Heterogeneity was observed in the
magnitude of the effect across the trials (I2 = 46.3%;
P = 0.02). However, after sequential exclusion of each
trial from all pooled analysis, the conclusion was not af-
fected by the exclusion of any specific trial. In a cumula-
tive meta-analysis for total mortality (Additional file 5:
Figure S4), the originally proposed significant omega-3
fatty acid effect was refuted by evidence accumulated up
to 2003 and has continued to linger around a small ef-
fect and borderline statistical significance.
Heterogeneity testing for the analysis showed a P > 0.10
for cancer incidence and nonvascular death. We con-
cluded that heterogeneity is not significant in the overall
analysis, suggesting that most variation was attributable
to chance alone. However, substantial heterogeneity
was observed in the magnitude of the effect for total mor-
tality across the trials. We, therefore, conducted a meta-
regression [24] analysis including sample size, mean age,
percent men, and duration of the follow-up. However,
these variables did not seem to be important factors
contributing to the association between omega-3 fatty
acid supplementation and total mortality risk (sample size,
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Figure 2 Effect of omega-3 fatty acid supplementation on the risk of cancer incidence.
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and duration of follow-up, P = 0.786).
Subgroup analyses were also conducted for cancer in-
cidence, nonvascular death, and total mortality to evalu-
ate the effect of omega-3 fatty acid supplementation in a
specific population. We noted that omega-3 fatty acid
supplementation was associated with a reduction in total
mortality risk if the trials were published before 2000,
the number of individuals in the study was less than
1000, the proportion of men in the study was more than
80%, or participants received alpha-linolenic acid. No
other significant differences were identified in pre-
defined factors between those who took omega-3 fatty
acid or placebo. Furthermore, there was no other signifi-
cant difference in the effects of omega-3 fatty acid be-
tween the 2 subgroups by factors that could affect the
treatment effects (Table 2).
A review of funnel plots could not rule out the poten-
tial for publication bias for lung cancer (AdditionalFigure 3 Effect of omega-3 fatty acid supplementation on the risk offile 6: Figure S5). The Egger [26] and Begg test [27] re-
sults showed no evidence of publication bias for cancer
incidence (Egger: P = 0.663; Begg: P = 0.876), nonvascular
death (Egger: P = 0.519; Begg: P = 0.620), and total mor-
tality (Egger: P = 0.255; Begg: P = 0.174).
Discussion
Several previous observational studies [1-3] have sug-
gested that omega-3 fatty acid supplementation has a
marked effect on cancer incidence. Kato and colleague
[1] performed a prospective study of omega-3 fatty acid
(fish or shellfish diet) and colorectal cancer in New York
and Florida. This prospective study included 14724 indi-
viduals and found a 51% reduction in the risk of colorec-
tal cancer with omega-3 fatty acid dietary consumption.
Furthermore, Takezaki et al. [2] concluded that frequent
fresh fish consumption, irrespective of the cooking
method, might reduce the risk of lung cancer. However,
the effect of omega-3 fatty acid supplementation innonvascular death.
Figure 4 Effect of omega-3 fatty acid supplementation on the risk of total mortality.
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http://www.biomedcentral.com/1471-2458/14/204reducing the risk of incident cancer has not been con-
firmed by randomized controlled trials and meta-
analysis.
Previous systematic review [36] have evaluated the im-
pact of omega-3 fatty acid supplementation on cancer
incidence on the basis of observational studies. These
studies encompass a large body of literature spanning
numerous cohorts, from many countries, with different
demographic characteristics and do not provide any
evidence to support a significant association between
omega-3 fatty acid and cancer incidence. Our study was
based solely on randomized controlled trials and ex-
plored all possible correlations between omega-3 fatty
acid supplementation and the outcomes of cancer inci-
dence, nonvascular death, and total mortality. This large
quantitative study included 68,954 individuals from 19
trials with a broad range of baseline characteristics. The
results of our meta-analysis suggest that omega-3 fatty
acid supplementation has no effect on the incidence of
cancer, nonvascular death, and total mortality.
Our main findings are inconsistent with the findings
of previous epidemiologic research [1-3], and concluded
that omega-3 fatty acid supplementation had no signifi-
cant benefit or adverse effect on the risk of cancer inci-
dence, nonvascular death or total mortality. The reason
for this could be that observational studies may overesti-
mate the effect of omega-3 supplementation.
There was no significant difference between omega-3
fatty acid supplementation and the placebo for the rela-
tive risk of cancer incidence. Omega-3 fatty acids do not
seem to affect a mechanism of cancer development that
is common across the different types of cancers evalu-
ated in this study. Previous observational studies [1-3]
suggested that risk reductions were observed for colo-
rectal, lung, and prostate cancer. However, data on any
specific cancer type were unavailable in this study;therefore, we did not identify the association between
any specific type of cancer incidence and omega-3 fatty
acid supplementation. According to our study, omega-3
fatty acid supplementation resulted in a 10% increase in
the risk of cancer incidence, but this difference was not
statistically significant. The possible reasons for this lack
of significant effect are as follows: (1) the use of back-
ground omega-3 fatty acid supplementation might have
impaired our ability to identify a treatment effect, and
(2) trials included were designed to evaluate the effects
of omega-3 fatty acid supplementation on cardiovas-
cular outcomes, but not cancer-related outcomes, these
results were derived from very few cases and should be
regarded as preliminary results. Furthermore, high in-
take of omega-3 fatty acid might stimulate carcinogen-
esis by increasing oxidative DNA damage [37]. Finally,
studies with an open, controlled design may have intro-
duced behavioral differences which may have had an im-
pact on the development of cancer. Therefore, although
omega-3 fatty acid supplementation may have direct
effects on cancer incidence, these effects may be bal-
anced. Furthermore, subgroup analysis also supports
that omega-3 fatty acid supplementation does not affect
cancer incidence.
Omega-3 fatty acid supplementation might play an im-
portant role in reducing the risk of total mortality, due
to the improved effects on cardiac death [38]. Our study
suggests that omega-3 fatty acid produced a 5% reduc-
tion in total mortality; however, this reduction was not
statistically significant. The reason for this absence of
statistical difference could be that omega-3 fatty acids
have no effect on the risk of nonvascular death. Hence,
this effect may be reduced by nonvascular death. Sub-
group analysis was also conducted on total mortal risk
based on pre-defined factors. We noted that omega-3
fatty acid supplementation reduced the risk of total
Table 2 Subgroup analysis for the effect of omega–3 fatty acid supplementation on cancer incidence, nonvascular death, and total mortality
Outcomes Group Number of study RR and 95% CI P value Heterogeneity (%) P value for heterogeneity P value for interaction test
Cancer incidence Publication year
Before 2000 5 1.07 (0.85–1.34) 0.56 0 0.87 0.789
After 2000 6 1.11 (0.96–1.28) 0.15 0 0.93
Number of patients
>1000 5 1.10 (0.97–1.24) 0.12 0 0.98 0.878
<1000 6 1.03 (0.45–2.38) 0.94 0 0.83
Percent men (%)
>80 7 1.06 (0.87–1.28) 0.58 0 0.98 0.608
<80 4 1.13 (0.97–1.31) 0.13 0 0.72
Mean age
>64 1 5.00 (0.24–103.28) 0.30 – – 0.328
<64 10 1.10 (0.97–1.24) 0.13 0 1.00
Intervention
Alpha–linolenic acid 1 0.33 (0.01–8.09) 0.50 – – 0.481
Long–chain n–3 PUFA 10 1.10 (0.98–1.24) 0.12 0 0.99
Primary or secondary prevention
Primary 1 1.11 (0.93–1.33) 0.26 – – 0.882
Secondary 10 1.09 (0.93–1.28) 0.29 0 0.98
Duration of the follow–up period (months)
>36 4 1.10 (0.97–1.24) 0.14 0 0.98 0.883
<36 7 1.16 (0.58–2.33) 0.68 0 0.88
Jadad score
>4 6 1.11 (0.96–1.30) 0.16 0 0.98 0.771
<4 5 1.07 (0.88–1.30) 0.49 0 0.77
Nonvascular death Publication year
Before 2000 5 0.93 (0.77–1.13) 0.47 0 0.82 0.440
After 2000 11 1.01 (0.93–1.10) 0.75 0 0.86
Number of patients
>1000 8 1.01 (0.93–1.09) 0.89 0 0.89 0.328
<1000 8 0.77 (0.45–1.32) 0.34 0 0.80
Percent men (%)
>80 9 0.93 (0.80–1.08) 0.37 0 0.78 0.219



















Table 2 Subgroup analysis for the effect of omega–3 fatty acid supplementation on cancer incidence, nonvascular death, and total mortality (Continued)
Mean age
>64 7 1.01 (0.86–1.19) 0.89 0 0.83 0.916
<64 9 1.00 (0.91–1.09) 0.94 0 0.78
Intervention
Alpha–linolenic acid 3 0.95 (0.32–2.85) 0.93 0 0.54 0.927
Long–chain n–3 PUFA 13 1.00 (0.93–1.08) 1.00 0 0.89
Primary or secondary prevention
Primary 3 1.01 (0.87–1.18) 0.87 31.6 0.23 0.754
Secondary 13 0.98 (0.88–1.10) 0.78 0 0.97
Duration of the follow–up period (months)
>36 7 0.99 (0.92–1.08) 0.85 0 0.68 0.460
<36 9 1.11 (0.83–1.49) 0.49 0 0.92
Jadad score
>4 8 1.02 (0.93–1.11) 0.71 0 0.62 0.427
<4 8 0.95 (0.82–1.11) 0.54 0 0.97
Total mortality Publication year
Before 2000 5 0.79 (0.67–0.93) 0.005 19 0.30 0.009
After 2000 12 1.00 (0.94–1.08) 0.90 29 0.16
Number of patients
>1000 9 0.98 (0.91–1.06) 0.57 57 0.02 0.014
<1000 8 0.67 (0.50–0.90) 0.007 0 0.59
Percent men (%)
>80 9 0.80 (0.65–0.98) 0.03 64 0.005 0.033
<80 7 1.01 (0.95–1.08) 0.71 0 0.84
Mean age
>64 7 0.96 (0.89–1.02) 0.20 0 0.44 0.543
<64 10 0.92 (0.82–1.04) 0.18 62 0.004
Intervention
Alpha–linolenic acid 3 0.58 (0.35–0.98) 0.04 0 0.46 0.058
Long–chain n–3 PUFA 14 0.96 (0.89–1.04) 0.36 47 0.03
Primary or secondary prevention
Primary 3 0.99 (0.86–1.14) 0.91 46 0.15 0.566



















Table 2 Subgroup analysis for the effect of omega–3 fatty acid supplementation on cancer incidence, nonvascular death, and total mortality (Continued)
Duration of the follow–up period (months)
>36 8 0.98 (0.91–1.05) 0.54 47 0.06 0.157
<36 9 0.80 (0.61–1.05) 0.11 43 0.08
Jadad score
>4 9 0.98 (0.91–1.06) 0.65 30 0.18 0.320
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http://www.biomedcentral.com/1471-2458/14/204mortality only when we included trials published before
2000, the sample size was less than 1000, the proportion
of men in the population was more than 80%, or partici-
pants received alpha-linolenic acid. The reason for these
findings could be that several factors might affect the ef-
ficacy of treatment, which happened to occur more fre-
quently in male patients, such as smoking status.
The limitations of our study are as follows: (1) rela-
tively few events of cancer incidence were reported,
which always contributed to broad confidence intervals,
and restricted us from obtaining an intrinsic effect; (2)
different types of supplements might provide a biased
view of the study question; (3) data on any specific type
of cancer were unavailable, due to which we could not
identify the association between any specific type of can-
cer incidence and omega-3 fatty acid supplementation;
and (4) since inherent assumptions are made for any
meta-analysis, the analysis used pooled data, and indi-
vidual patient data was not available, which restricted us
from performing a more detailed relevant analysis and
obtaining more comprehensive results.
Conclusions
The findings of this study suggest that omega-3 fatty
acid supplementation has no significant effects on can-
cer incidence, nonvascular death, or total mortality. Fu-
ture studies should focus on healthy individuals to
analyze the primary prevention of cancer incidence. We
suggest that ongoing trials should be improved in the
following ways: (1) any specific type of cancer and total
cancer incidents should be recorded and reported nor-
matively, and it should be evaluated in any future trial,
and (2) the role of intervention duration and dosage of
supplementation should be taken into consideration be-
fore evaluating clinical outcomes.
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